Trip Hornick predicts that China will never completely cut off the U.S. from its rare earth supply.

India is 100% reliant on China for its supply of pharmaceutical precursors.

The United States can become 100% self-reliant for its critical mineral needs.

The United States is 90% reliant on India for its pharmaceutical precursors and generics.

The primary bottleneck in the U.S. rare earth supply chain is the lack of mid-supply chain processing capabilities, not a shortage of raw materials.

The current U.S. administration is taking equity positions in companies it invests in as a way to ensure a return to the taxpayer.

The United States has 95% of the rare earth raw materials it needs located within the contiguous 48 states.

The United States produces almost no generic drugs domestically.